A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients

BackgroundTumor-associated macrophages (TAMs) are classified into two major phenotypes, M1 and M2. M1 TAMs suppress cancer progression, while M2 TAMs promote it. However, little is known regarding the role of TAMs in the development of ovarian cancer. Here, we investigated the relationship between TAM distribution patterns (density, microlocalization, and differentiation) and ovarian cancer histotypes, and we explored whether altered TAM distribution patterns influence long-term outcomes in ovarian cancer patients.MethodsA total of 112 ovarian cancer patients were enrolled in this study, and the subjects were divided into two groups according to their survival (< 5 years vs. ≥ 5 years). Immunohistochemistry and immunofluorescence were used to determine the density, microlocalization, and differentiation status of TAMs in ovarian cancer tissues for each histotype. Kaplan-Meier survival and multivariate Cox regression analyses were used to evaluate the prognostic significance of TAM-related parameters in ovarian cancer.ResultsTAMs most frequently infiltrated into the cancer tissue of the serous histotype, followed by mucinous, undifferentiated, endometrioid, and clear cell histotypes (p = 0.049). The islet/stroma ratio of total TAMs varied among the cancer histotypes, with mucinous and undifferentiated cancers displaying the lowest and highest ratios, respectively (p = 0.005). The intratumoral TAM density significantly increased with increasing cancer stage and grade (p = 0.023 and 0.006, respectively). However, the overall M1/M2 TAM ratio decreased as the cancer stage increased (p = 0.012). In addition, the intra-islet M1/M2 ratio inversely correlated with the residual site size (p = 0.004). Among the TAM-related parameters, only the increased overall and intra-islet M1/M2 TAM ratios displayed prognostic significance in both the Kaplan-Meier survival and multivariate Cox regression analyses; however, the values of these two parameters did not differ significantly among the cancer histotypes.ConclusionsThe patients with increased overall or intra-islet M1/M2 TAM ratios presented with an improved 5-year prognosis. Nevertheless, the TAM distribution patterns did not influence the overall outcomes of different ovarian cancer histotypes.

[1]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[2]  Lynette M. Smith,et al.  Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16 (CA125) , 2006, Modern Pathology.

[3]  Kwun Chuen Gary Chan,et al.  p53 autoantibodies, cytokine levels and ovarian carcinogenesis. , 2009, Gynecologic oncology.

[4]  I. Ugrinova,et al.  The expression of HMGB1 protein and its receptor RAGE in human malignant tumors , 2010, Molecular and Cellular Biochemistry.

[5]  R. Reznek,et al.  Ovarian Cancer Management: the role of imaging and diagnostic challenges. , 2011, European journal of radiology.

[6]  R. Hodges,et al.  Tear film mucins: front line defenders of the ocular surface; comparison with airway and gastrointestinal tract mucins. , 2013, Experimental eye research.

[7]  F. Ajili,et al.  Prognostic Value of Tumor-associated Macrophages Count in Human Non-muscle-invasive Bladder Cancer Treated by BCG Immunotherapy , 2013, Ultrastructural pathology.

[8]  S. Natsugoe,et al.  Tumor-associated macrophage (TAM) infiltration in gastric cancer. , 2003, Anticancer research.

[9]  H. Kawashima.  Roles of the gel-forming MUC2 mucin and its O-glycosylation in the protection against colitis and colorectal cancer. , 2012, Biological & pharmaceutical bulletin.

[10]  G. Enikolopov,et al.  Ovarian surface epithelium at the junction area contains cancer-prone stem cell niche , 2013, Nature.

[11]  P. Bradding,et al.  Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival , 2009, European Respiratory Journal.

[12]  B. Davidson,et al.  Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. , 2013, Human pathology.

[13]  Ruedi Aebersold,et al.  Protein expression changes in ovarian cancer during the transition from benign to malignant. , 2012, Journal of proteome research.

[14]  S. Vandenberg,et al.  Myeloid cell receptor LRP1/CD91 regulates monocyte recruitment and angiogenesis in tumors. , 2013, Cancer research.

[15]  M. Schiff,et al.  Ovarian cancer incidence and mortality in American Indian, Hispanic, and non-Hispanic white women in New Mexico. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[16]  A. Harris,et al.  Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer , 2000, The Journal of pathology.

[17]  B. Melichar,et al.  Phenotype and antitumor activity of ascitic fluid monocytes in patients with ovarian carcinoma , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[18]  Y. Kanai,et al.  Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer , 2013, British Journal of Cancer.

[19]  G. Fuller,et al.  Intratumoral Mediated Immunosuppression is Prognostic in Genetically Engineered Murine Models of Glioma and Correlates to Immunotherapeutic Responses , 2010, Clinical Cancer Research.

[20]  M. Bäckström,et al.  Increased Understanding of the Biochemistry and Biosynthesis of MUC2 and Other Gel-Forming Mucins Through the Recombinant Expression of Their Protein Domains , 2013, Molecular Biotechnology.

[21]  Andrew J. Wilson,et al.  Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model , 2013, Journal of Ovarian Research.

[22]  I. Căruntu,et al.  Ovarian cancer: insights into genetics and pathogeny. , 2012, Histology and histopathology.

[23]  A. Endo,et al.  Expression of arginase by mouse myeloid leukemic cell differentiation in vitro induced with tumor necrosis factor. , 1991, The Journal of veterinary medical science.

[24]  K. Pienta,et al.  Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. , 2010, Journal of the National Cancer Institute.

[25]  L. Zitvogel,et al.  The immunogenicity of tumor cell death , 2009, Current opinion in oncology.

[26]  A. Mantovani,et al.  Effects on in vitro tumor growth of macrophages isolated from human ascitic ovarian tumors , 1979, International journal of cancer.

[27]  D. Bowtell,et al.  Identification of Novel Therapeutic Targets in Microdissected Clear Cell Ovarian Cancers , 2011, PloS one.

[28]  B. Mukherji.  In vitro assay of spontaneous cytotoxicity by human monocytes and macrophages against tumor cells. , 1980, Journal of immunological methods.

[29]  A. Doseff,et al.  Regulation of monocytes and macrophages cell fate. , 2009, Frontiers in bioscience.

[30]  P. Allavena,et al.  Engagement of the Mannose Receptor by Tumoral Mucins Activates an Immune Suppressive Phenotype in Human Tumor-Associated Macrophages , 2011, Clinical & developmental immunology.

[31]  J. Prat.  Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features , 2012, Virchows Archiv.

[32]  W. McCluggage,et al.  Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. , 2011, Pathology.

[33]  S. Batra,et al.  Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer. , 2008, The Lancet. Oncology.

[34]  H. Baba,et al.  Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma , 2010, Cancer science.

[35]  Ie-Ming Shih,et al.  The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.

[36]  R. Palmqvist,et al.  High Macrophage Infiltration along the Tumor Front Correlates with Improved Survival in Colon Cancer , 2007, Clinical Cancer Research.

[37]  Robert N. Taylor,et al.  Infiltration of Tumor-associated Macrophages is Increased in the Epithelial and Stromal Compartments of Endometrial Carcinomas , 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[38]  G. Opdenakker,et al.  Cytokines and proteases in invasive processes: molecular similarities between inflammation and cancer. , 1992, Cytokine.

[39]  H. Nishitani,et al.  Prognostic Significance of HIF-2alpha Expression on Tumor Infiltrating Macrophages in Patients with FIGO Stage IIIb Uterine Cervical Cancer undergoing Radiotherapy , 2008 .

[40]  E. Stanley,et al.  Colony-Stimulating Factor-1 Blockade by Antisense Oligonucleotides and Small Interfering RNAs Suppresses Growth of Human Mammary Tumor Xenografts in Mice , 2004, Cancer Research.

[41]  E. Mendonça,et al.  Tumor-associated macrophages and the profile of inflammatory cytokines in oral squamous cell carcinoma. , 2013, Oral oncology.

[42]  Ti Zhang,et al.  Correlations of tumor-associated macrophage subtypes with liver metastases of colorectal cancer. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[43]  K. Kosarin,et al.  Selection of Endometrial Carcinomas for DNA Mismatch Repair Protein Immunohistochemistry Using Patient Age and Tumor Morphology Enhances Detection of Mismatch Repair Abnormalities , 2009, The American journal of surgical pathology.

[44]  Y. Kim,et al.  Immunohistochemical study of mucin carbohydrates and core proteins in human ovarian tumors. , 1994, Human pathology.

[45]  M. Nakagawa,et al.  Prognostic value of tumor‐associated macrophage count in human bladder cancer , 2000, International journal of urology : official journal of the Japanese Urological Association.

[46]  S. Gordon,et al.  Biology of the Macrophage , 1986, Journal of Cell Science.

[47]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.

[48]  K. Shimada,et al.  Immunohistochemical Analysis of Inflammatory Cells in Benign and Precancerous Lesions and Carcinoma of the Prostate , 2013, Pathobiology.

[49]  M. Cummings,et al.  Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours , 1997, The Journal of pathology.

[50]  R. Ozols,et al.  CA‐125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers , 2009, Cancer.

[51]  J. Pollard,et al.  Distinct role of macrophages in different tumor microenvironments. , 2006, Cancer research.

[52]  R. Kempf,et al.  Cytotoxic activity of human pulmonary alveolar macrophages. , 1985, Cancer research.

[53]  A. Mackiewicz,et al.  Therapeutic gene modified cell based cancer vaccines. , 2013, Gene.

[54]  R. Bristow,et al.  Surgical Management of Epithelial Ovarian Cancer , 2012, Clinical obstetrics and gynecology.

[55]  Shan Wang,et al.  IL10, IL11, IL18 are differently expressed in CD14+ TAMs and play different role in regulating the invasion of gastric cancer cells under hypoxia. , 2012, Cytokine.

[56]  R. Palmqvist,et al.  The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal Cancer , 2012, PloS one.

[57]  C. Jacobi,et al.  Induction of M2-macrophages by tumour cells and tumour growth promotion by M2-macrophages: a quid pro quo in pancreatic cancer. , 2013, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[58]  H. Grossniklaus,et al.  M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles. , 2013, Experimental eye research.

[59]  E. Oliva,et al.  Precursors and pathogenesis of ovarian carcinoma , 2013, Pathology.

[60]  E. Morii,et al.  Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma , 2011, Virchows Archiv.

[61]  H. Cha,et al.  Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. , 2008, Cancer research.

[62]  Kristi Kincaid,et al.  M-1/M-2 Macrophages and the Th1/Th2 Paradigm1 , 2000, The Journal of Immunology.

[63]  P. Stattin,et al.  Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. , 2000, International journal of oncology.

[64]  K. Wong,et al.  Incidence, mortality, and survival trends of ovarian cancer in Hong Kong, 1997 to 2006: a population-based study. , 2012, Hong Kong medical journal = Xianggang yi xue za zhi.

[65]  J. Perez-Vilar,et al.  Gel-forming mucins. Notions from in vitro studies. , 2007, Histology and histopathology.

[66]  Hideo Nakamura,et al.  Importance of direct macrophage ‐ Tumor cell interaction on progression of human glioma , 2012, Cancer science.

[67]  P. Allavena,et al.  Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. , 2009, Human immunology.

[68]  E. Giannoni,et al.  Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression , 2014, Oncogene.

[69]  Yuquan Wei,et al.  Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature , 2012, PloS one.

[70]  T. Sano,et al.  Prognostic significance of HIF-2alpha expression on tumor infiltrating macrophages in patients with uterine cervical cancer undergoing radiotherapy. , 2008, The journal of medical investigation : JMI.

[71]  Karin Jirström,et al.  The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients , 2012, BMC Cancer.

[72]  L. Tafe,et al.  Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms , 2010, Modern Pathology.

[73]  A. Montag,et al.  Differential expression of MUC2 and MUC5AC mucin genes in primary ovarian and metastatic colonic carcinoma. , 2000, Human pathology.

[74]  X. Chen,et al.  Density of tumor-associated macrophages correlates with lymph node metastasis in papillary thyroid carcinoma. , 2012, Thyroid : official journal of the American Thyroid Association.

[75]  T. Fujiwara,et al.  Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  P. Allavena,et al.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.

[77]  Mitchell Ho,et al.  Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors , 2006, Molecular Cancer.

[78]  Lunxu Liu,et al.  The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time , 2010, BMC Cancer.

[79]  Kathleen R. Cho,et al.  Classifications of ovarian cancer tissues by proteomic patterns , 2006, Proteomics.

[80]  Andrew V. Nguyen,et al.  Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.

[81]  Zhao-You Tang,et al.  The Clinical Significance of the CD163+ and CD68+ Macrophages in Patients with Hepatocellular Carcinoma , 2013, PloS one.

[82]  H. Kitchener,et al.  Staging Classifications and Clinical Practice: Guidelines for Gynaecologic Cancers , 2003 .

[83]  T. Komori,et al.  Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma , 2013, Cancer science.

[84]  T. Hla,et al.  Induction of cyclooxygenase-2 in monocyte/macrophage by mucins secreted from colon cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.